MMTP indicates methadone maintenance treatment program. MMTP patients with any pain (313/390 [80%]) and inpatients with any pain (412/531 [78%]) include chronic severe pain as well as any pain in the past week. Pain severity was measured on the Brief Pain Inventory item "pain at its worst" in the past week.

Patterns of pain associated with specific degenerative changes are shown in red. A, Early degenerative changes of the functional spinal unit include loss of hydration of the nucleus pulposus accompanied by mild loss of height of the intervertebral disk. Internal disk disruption (left) begins with radial and/or concentric fissures that extend from the periphery of the nucleus pulposus into the annulus fibrosus. Extension of these fissures or of material from the nucleus pulposus to the peripheral portion of the annulus fibrosis can produce lumbosacral pain mediated by the sinuvertebral nerve. Extension of material from the nucleous pulposus posterolaterally outside the annulus fibrosis (herniated nucleus pulposus, right) can produce an intense inflammatory reaction surrounding the spinal nerve leading to radicular pain. B, Advanced degenerative changes include complete loss of hydration of the nucleus pulposus, marked loss of height of the intervertebral disk, osteophyte formation, and thickening of ligaments. Central canal stenosis results from the combined effects of facet hypertrophy and thickening of the ligamentum flavum and posterior longitudinal ligaments. These degenerative changes can produce neurogenic claudication. Progressive degeneration of the disk or facets can produce chronic lumbosacral pain. Facet hypertrophy can produce stenosis of the lateral recess of the spinal canal and the intervertebral foramen, which may result in radicular pain.

SPs indicates standardized patients; LBP, low back pain; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; and CAD, coronary artery disease. P values are for 4-way analysis of variance comparing the 3 quality evaluation methods for specific conditions. Data presented as percentage ±SD correct.

A, The patient had a left medial ankle ulcer of 17 years' duration. B, One day after hospital admission with vaso-occlusive pain crisis, the patient developed a pulmonary infiltrate, encephalopathy, and renal insufficiency. Induced sputum demonstrated lipid-laden macrophages by oil red O stain (magnification x 1000), which is indicative of fat embolus to the lung from infarcted marrow. C, Approximately 2 weeks later, the patient presented with acute dysarthria and right-hand weakness. Diffusion-weighted magnetic resonance imaging (MRI) showed a bright signal in the left hemisphere (left image, arrowhead), indicating acute edema and new stroke. Additional images at the same time using the FLAIR technique (fluid-attenuated inversion recovery) demonstrated right frontal lobe cavitation (right image, left [blue] arrowhead) and chronic watershed zone infarcts (right image, right [yellow] arrowhead) from previously unsuspected ischemic strokes. Magnetic resonance angiography revealed nearly absent flow in the internal carotid arteries (not shown).

National Kidney Foundation Kidney Disease Outcomes Quality Initiative chronic kidney disease stages: 1, glomerular filtration rate (GFR) of 90 mL/min per 1.73 m² or greater; 2-4, GFR of 15 to 89 mL/min per 1.73 m²; 5, GFR of less than 15 mL/min per 1.73 m². Persons with no kidney disease initially can develop proteinuria, progress to chronic renal insufficiency, progress to end-stage renal disease, and die. Most frequent pathways are denoted by heavy arrows. Blue dashed lines represent slower progression based on benefit from angiotensin-converting enzyme (ACE) inhibitor or angiotensin II-receptor blocker (ARB) therapy. Persons who are in the "no screening" (usual care) group do not benefit from ACE inhibitor or ARB therapy unless disease is detected via incidental testing or testing performed as a result of patient symptoms (eg, leg swelling, dysuria, flank pain), which is indicated by the upward arrows from the no screening path to the screening path. The transition from no kidney disease directly to death is not shown but was incorporated into the model.